MicroGenDX Announces Acquisition of RTL Genomics to Advance Primary Research in DNA Sequencing
Since 2008, MicroGenDX has been perfecting a mature bioinformatics pipeline for its targeted 16S and ITS NGS clinical testing, which has allowed the company to become the industry leader in highly accurate, rapid-turnaround, low-cost molecular diagnostics. The carefully curated MicroGenDX reference database now contains over 50,000 microbial species. With the addition of RTL Genomics lab resources and experienced staff, MicroGenDX and RTL Genomics aim to replicate the same bioinformatics success with whole genome sequencing.
"Developing a comprehensive reference database for shotgun sequencing is our long-term goal," says Eric Rees, CTO of MicroGenDX. "By evaluating and comparing the bioinformatic performance of our clinical and research workflows, we can now expand datasets and refine our software for both much more rapidly. The capabilities of MicroGenDX and RTL Genomics complement each other very well."
MicroGenDX's acquisition of RTL Genomics is a reunion. Both labs were originally separate divisions of the same company, Southwest Regional PCR, and both are located in Lubbock, Tex. In 2017, MicroGenDX and RTL Genomics separated into two independent businesses.
Founded in 2008, MicroGenDX has become the industry leader in rapid turnaround and affordability for comprehensive Next-Generation Sequencing (NGS) and qPCR testing for clinical diagnostics. MicroGenDX is CLIA-licensed and CAP-accredited, and has been the trusted research partner for the CDC, U.S. Army, NASA and the FDA. MicroGenDX has published over 35 clinical trials and is the most experienced molecular diagnostic laboratory with some 1.5 million samples processed. Over 80,000 medical professionals rely on MicroGenDX clinical diagnostics.
MicroGenDX also offers over 30 specialized clinical diagnostic tests for a comprehensive array of medical specialties and infection types. For more information, visit www.microgendx.com or www.rtlgenomics.com